yahoo_financeOriginal article
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Trial StartIn Vivo CAR-TPositive
AI Analysis
Summary
Tempest Therapeutics unveiled its next-generation in vivo CAR-T pipeline with plans to initiate the first clinical study in Q4 2026.
Clinical Trial Data
Phase
1
Outcome Details
First clinical study planned for Q4 2026
Importance:6/10
Sentiment:
0.60
CAR-TPipelineClinical TrialOncology
Related Companies
Read the original article
Published by yahoo_finance on July 15, 2026 11:00 AM